- Home
- FBRX vs INKT Comparison
FBRX vs INKT Comparison
Compare FBRX & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBRX
- INKT
- Stock Information
- Founded
- FBRX N/A
- INKT 2017
- Country
- FBRX United States
- INKT United States
- Employees
- FBRX N/A
- INKT N/A
- Industry
- FBRX Biotechnology: Pharmaceutical Preparations
- INKT Medicinal Chemicals and Botanical Products
- Sector
- FBRX Health Care
- INKT Health Care
- Exchange
- FBRX Nasdaq
- INKT Nasdaq
- Market Cap
- FBRX 35.3M
- INKT 33.6M
- IPO Year
- FBRX N/A
- INKT 2021
- Fundamental
- Price
- FBRX $5.97
- INKT $7.61
- Analyst Decision
- FBRX Strong Buy
- INKT Strong Buy
- Analyst Count
- FBRX 3
- INKT 2
- Target Price
- FBRX $80.50
- INKT $37.50
- AVG Volume (30 Days)
- FBRX 32.5K
- INKT 4.9K
- Earning Date
- FBRX 05-12-2025
- INKT 05-13-2025
- Dividend Yield
- FBRX N/A
- INKT N/A
- EPS Growth
- FBRX N/A
- INKT N/A
- EPS
- FBRX N/A
- INKT N/A
- Revenue
- FBRX N/A
- INKT N/A
- Revenue This Year
- FBRX N/A
- INKT N/A
- Revenue Next Year
- FBRX N/A
- INKT N/A
- P/E Ratio
- FBRX N/A
- INKT N/A
- Revenue Growth
- FBRX N/A
- INKT N/A
- 52 Week Low
- FBRX $4.11
- INKT $4.56
- 52 Week High
- FBRX $28.68
- INKT $13.79
- Technical
- Relative Strength Index (RSI)
- FBRX 42.87
- INKT 44.24
- Support Level
- FBRX $5.25
- INKT $7.23
- Resistance Level
- FBRX $7.67
- INKT $7.68
- Average True Range (ATR)
- FBRX 0.92
- INKT 0.56
- MACD
- FBRX 0.17
- INKT -0.06
- Stochastic Oscillator
- FBRX 38.44
- INKT 21.66
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.